Compugen (NASDAQ:CGEN) Coverage Initiated at Oppenheimer

Research analysts at Oppenheimer started coverage on shares of Compugen (NASDAQ:CGEN) in a research note issued on Monday, MarketBeat.com reports. The brokerage set an “outperform” rating and a $4.00 price target on the biotechnology company’s stock. Oppenheimer’s price objective would suggest a potential upside of 100.00% from the stock’s previous close.

Compugen Trading Up 0.5 %

Shares of CGEN stock opened at $2.00 on Monday. Compugen has a 12 month low of $1.35 and a 12 month high of $3.03. The stock has a market cap of $178.47 million, a P/E ratio of 100.00 and a beta of 2.59. The company has a 50 day simple moving average of $1.58 and a two-hundred day simple moving average of $1.72.

Compugen (NASDAQ:CGEN) last posted its quarterly earnings data on Tuesday, November 12th. The biotechnology company reported $0.01 EPS for the quarter, missing the consensus estimate of $0.21 by ($0.20). Compugen had a return on equity of 2.62% and a net margin of 2.67%. The company had revenue of $17.13 million during the quarter, compared to analysts’ expectations of $17.67 million. During the same quarter last year, the company earned ($0.11) earnings per share. As a group, equities analysts forecast that Compugen will post 0.11 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in CGEN. Connor Clark & Lunn Investment Management Ltd. increased its holdings in Compugen by 82.7% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 274,335 shares of the biotechnology company’s stock worth $497,000 after acquiring an additional 124,190 shares in the last quarter. Atom Investors LP lifted its holdings in Compugen by 27.5% during the third quarter. Atom Investors LP now owns 151,816 shares of the biotechnology company’s stock valued at $275,000 after purchasing an additional 32,701 shares in the last quarter. Squarepoint Ops LLC boosted its position in shares of Compugen by 23.4% in the second quarter. Squarepoint Ops LLC now owns 85,693 shares of the biotechnology company’s stock worth $144,000 after purchasing an additional 16,253 shares during the period. Joel Isaacson & Co. LLC increased its stake in shares of Compugen by 136.4% in the third quarter. Joel Isaacson & Co. LLC now owns 52,000 shares of the biotechnology company’s stock worth $94,000 after purchasing an additional 30,000 shares in the last quarter. Finally, Oppenheimer & Co. Inc. raised its position in shares of Compugen by 75.9% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 19,350 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 8,350 shares during the period. Institutional investors own 12.22% of the company’s stock.

Compugen Company Profile

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company’s immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer.